AIHealthcare

Ataraxis AI is a New York-based AI precision-medicine company spun out of New York University. It develops AI-native cancer diagnostics and treatment-selection tools by combining digital pathology with clinical and other multimodal data. Its flagship offering, Ataraxis Breast, is designed to provide prognostic and predictive insights for breast-cancer patients, including recurrence risk and likely treatment benefit. The company also develops Kestrel, a foundation model for digital pathology, and positions its technology as an alternative or complement to conventional molecular diagnostics for personalized oncology care. Publicly reported evidence describes Ataraxis as an early-stage, privately held oncology-AI company moving from clinical validation toward commercial deployment; its claimed clinical performance and market adoption should be treated as company-reported unless independently validated.